Renal flare prediction and prognosis in lupus nephritis Hispanic patients
Abstract
We performed a retrospective cohort analysis focusing on lupus nephritis renal flare incidence and outcome predictors. One hundred and eighteen patients with biopsy-proven lupus nephritis were segregated by induction/maintenance regimes. The primary outcome was the proportion of patients experiencing renal flare. Secondary assessment included doubling of serum creatinine and development of end-stage renal disease. After a median follow-up of 31 months (interquartile range 21–46) from the date of response to induction therapy, 47 patients (39.8%) developed a renal flare. Azathioprine-maintained patients had a higher risk of renal flare compared with mycophenolate mofetil-maintained patients (hazard ratio 2.53, 95% confidence interval 1.39–4.59, p < 0.01). Age (hazard ratio 0.96, 0.92–0.99, p = 0.03), serum creatinine at presentation (hazard ratio 1.76, 1.13–2.76, p = 0.01), complete remission after induction therapy (hazard ratio 0.28, 0.14–0.56, p < 0.001) and azathioprine maintenance therapy (hazard ratio 4.78, 2.16–10.6, p < 0.001) were associated with renal flare on multivariate analysis. Ten patients progressed to end-stage renal disease (8.5%) by a median 32.5 months. Age (hazard ratio 0.88, 0.77–0.99, p = 0.05), complete remission after induction therapy (hazard ratio 0.08, 0.01–0.94, p = 0.04) and severe nephritic flare (hazard ratio 13.6, 1.72–107.7, p = 0.01) were associated with end-stage renal disease development. Azathioprine maintenance therapy is associated with a higher incidence of relapse in the Mexican-mestizo population. Younger age and nephritic flares predict development of end-stage renal disease.
Get full access to this article
View all access and purchase options for this article.
References
1. Dooley MA Clinical and laboratory features of lupus nephritis. In: Wallace DJ, Hahn BH (eds). Dubois’s lupus erythematosus, Philadelphia, PA: Lippincott Williams & Wilkins, 2007, pp. 1112–1130.
2. Danila MI, Pons-Estel GJ, Zhang J, Vilá LM, Reveille JD, Alarcón GS. Renal damage is the most important predictor of mortality within the damage index: Data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 2009; 48: 542–545.
3. Lenz O, Waheed AA, Baig A, Pop A, Contreras G. Lupus nephritis: Maintenance therapy for lupus nephritis – do we now have a plan? Clin J Am Soc Nephrol 2013; 8: 162–171.
4. Morris HK, Canetta PA, Appel GB. Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis. Nephrol Dial Transplant 2013; 28: 1371–1376.
5. Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: Long-term follow-up. Nephrol Dial Transplant 2006; 21: 1541–1548.
6. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticellli C. ‘Nephritic flares’ are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 2047–2053.
7. Sidiropoulos PI, Kritikos HD, Boumpas DT. Lupus nephritis flares. Lupus 2005; 14: 49–52.
8. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy. Long term follow up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46: 995–1002.
9. Contreras G, Pardo V, Leclerq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971–980.
10. Houssiau FA, D’Cruz D, Sangle S, et al. MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for maintenance immunosuppression of proliferative lupus nephritis: Results of a randomized trial. Ann Rheum Dis 2010; 69: 2083–2089.
11. Dooley MA, Jayne D, Ginzler EM, et al., ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886–1895.
12. Burgos PI, McGwin G Jr, Pons-Estel GJ, Reveille JD, Alarcón GS, Vilá LM. US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course; data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis 2010; 70: 393–394.
13. Korbet SM, Schwartz MM, Evans J, Lewis EJ. Collaborative Study Group. Severe lupus nephritis: Racial differences in presentation and outcome. J Am Soc Nephrol 2007; 18: 244–254.
14. Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006; 69: 1846–1851.
15. Austin HA III, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis: Contribution of renal histologic data. Am J Med 1983; 75: 382–391.
16. Gordon C, Jayne D, Adu D, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18: 257–263.
17. Rovin BH, Furie R, Latinis K, et al., LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215–1226.
18. Flehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K. Improved clinical outcome of lupus nephritis during the past decade: Importance of early diagnosis and treatment. Ann Rheum Dis 2003; 62: 435–439.
19. Mosca M, Bencivelli W, Neri R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002; 61: 1502–1509.
20. Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant 2007; 22: 2531–2539.
21. Ciruelo E, de la Cruz J, Lopez I, Gómez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996; 39: 2028–2034.
22. Mok CC, Ying KY, Tang S, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Ther 2004; 50: 2559–2568.
23. Chan TM, Tse KC, Tang CS, Lai KN, Li FK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005; 14: 265–272.
24. Donadio JV, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978; 299: 1151–1155.
25. Chan TM, Li FK, Tang CS, et al. For the Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156–1162.
26. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis; the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121–2131.
27. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ. Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008; 3: 46–53.
28. Mok CC, Ho CT, Chan DW, Lau CS, Wong RW. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002; 46: 1003–1013.
29. Morris HK, Canetta PA, Appel GB. Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis. Nephrol Dial Transplant 2013; 28: 1371–1376.
30. Tamirou F, D’Cruz D, Sangle S, et al.; and the MAINTAIN Nephritis Trial Group. Ann Rheum Dis (in press).
31. Mejía-Vilet JM, Arreola-Guerra JM, Córdova-Sánchez BM, et al. Comparison of lupus nephritis induction treatments in a hispanic population: a single-center cohort analysis. J Rheum 2015. Epub. DOI: 10.3899/jrheum.150395.
32. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258–264.
33. El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA. Relapses of lupus nephritis: Incidence, risk factors, serology and impact on outcome. Lupus 2003; 12: 692–696.
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: September 24, 2015
Issue published: March 2016
Keywords
PubMed: 26405028
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 478
*Article usage tracking started in December 2016
Altmetric
See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 28 view articles Opens in new tab
Crossref: 31
- Predictors of renal relapse in Koreans with lupus nephritis after achi...
- Diagnosis and treatment of lupus nephritis: a summary of the Consensus...
- Flares in Lupus Nephritis: Risk Factors and Strategies for Their Preve...
- Healthcare Resource Utilization and Associated Costs in Patients With ...
- The influence of repeated flares in response to therapy and prognosis ...
- Characteristics and outcomes of a Hispanic lupus nephritis cohort from...
- Documento de consenso del Grupo de Estudio de Enfermedades Glomerulare...
- Consensus document of the Spanish Group for the Study of the Glomerula...
- Altered B cell phenotype and CD27+ memory B cells are associated with ...
- Long-term outcome and predictors of long-term outcome in patients with...
- Renal outcomes of transient proteinuria in patients with systemic lupu...
- Lupus Nephritis: Improving Treatment Options
- C4d as a Screening Tool and an Independent Predictor of Clinical Outco...
- Outcomes of planned pregnancy in patients with systemic lupus erythema...
- Performance of the 2019 EULAR/ACR systemic lupus erythematosus classif...
- Kidney disease
- Machine Learning for Prediction and Risk Stratification of Lupus Nephr...
- An Update on the Diagnosis and Management of Lupus Nephritis
- Lupus nephritis
- Renal flare in class V lupus nephritis: increased risk in patients wit...
- Performance of cytokine models in predicting SLE activity
- Clinical Outcomes and Clinico-pathological Correlations in Lupus Nephr...
- Clinical manifestations, immunological features and prognosis of Chine...
- Epidemiology and Management of Lupus Nephritis
- Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patien...
- Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patien...
- Sustained complete renal remission is a predictor of reduced mortality...
- Longterm Data on Disease Flares in Patients with Proliferative Lupus N...
- Immunosuppressive treatment for pure membranous lupus nephropathy in a...
- Moderator's view: Cyclophosphamide in lupus nephritis
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
